Protocol Ledger

NCT05673785 · Phase II · ACTIVE NOT RECRUITING

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Interventional Phase II clinical trial protocol NCT05673785 sponsored by Takeda in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-10 Enrollment: 52 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05673785
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)52 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05673785
Protocol FieldVerified Registry Value
NCT IdentifierNCT05673785
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment52 participants (ACTUAL)
Registered Start Date2023-02-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05673785
Hospital Research SiteLocationSite Profile
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking University Third HospitalBeijing, ChinaOpen Hospital Dossier ->
The First Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->
West China Hospital,Sichuan UniversityChengdu, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI